

Title: Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R)

Decision: The Centers for Medicare & Medicaid Services (CMS) is expanding coverage for Next Generation Sequencing (NGS) as a diagnostic laboratory test that is reasonable and necessary and covered for patients with inherited ovarian or breast cancer when all applicable coverage requirements are met. The lab test using NGS must have FDA approval or clearance.

Medicare Administrative Contractors may determine coverage of diagnostic lab tests using NGS when a patient has any inherited cancer diagnosis when all applicable coverage requirements are met.

What this means: Next Generation Sequencing (NGS) as a diagnostic tool may be covered for members with inherited ovarian or breast cancer who meet the coverage indications. HealthPartners has discretion over whether to cover NGS for certain other indications according to coverage requirements established by the Medicare Administrative Contractors. Please refer to the final decision memo for all coverage criteria.

Effective: January 27, 2020

This announcement can be found at: [Next Generation Sequencing \(NGS\) for Medicare Beneficiaries with Advanced Cancer \(CAG-00450R\)](#)

HealthPartners is a health plan that contracts with both Medicare and the Minnesota Medical Assistance (Medicaid) program to provide benefits of both programs to enrollees. HealthPartners is also a Cost plan and PPO plan with a Medicare contract. Enrollment in HealthPartners depends on contract renewal. HealthPartners UnityPoint Health is a PPO plan with a Medicare contract. Enrollment in HealthPartners UnityPoint Health depends on contract renewal.

H2462_90242 IR Approved 06/2015
H3416_90242 IR Approved 06/2017
H2422_90242 IR Approved 07/2015
H4882_90242 IR Approved 03/2018